ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 371

Therapeutic Efficacy and Safety of Iguratimod in Treating Mild IgG4-Related Diseases

Wen Zhang1 and Panpan Zhang2, 1Rheuamtology, Peking Union Medical College Hospital, Beijing, China, 2Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: IgG4 Related Disease, immunosuppressants and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

To evaluate the therapeutic efficacy and safety of Iguratimod in the treatment of mild IgG4 related disease (IgG4-RD).

Methods: Thirty patients with newly diagnosed mild IgG4-RD were enrolled. One initial dose of diprospan, intramuscular injection, and Iguratimod, 25 mg, twice daily, at 0, 12 and 24 weeks, patients were followed up. Follow up indexes including physician global assessment (PGA), IgG4-RD responder index (IgG4-RD RI), serology and imaging, plasma cytokines and adverse drug effect. Flow cytometry technology was performed for the detection of T, B-cell subsets and plasma cells before and after treatment in patients.

Results: The ages of thirty-four patients with newly diagnosed mild IgG4-RD were 50.83±10.24 years old, and disease duration was 31.5 (8-66) months. The ratio of male to female was 1:1. The IgG4-RD RI of patients assessed at 0 weeks was 10.47±3.98. There was a significant decrease of IgG4-RD RI in patients following up at 12 weeks and 24 weeks, which was 3.60±2.44, 3.13±1.71, P<0.0001. Serum IgG and IgG4 levels at baseline were 22.16±9.54 g/L and 12250(5568-15625) mg/L, respectively. The IgG level at week 12 and week 24 was 15.42±6.15 g/L and 15.43±5.93 g/L respectively, and the IgG4 level was 4725 (2738-8748) mg/L and 6020(2613-11450) mg/L, which showed significantly reduction of serum IgG and IgG4, P values were both <0.0001 respectively. After treatment, CD3+CD8+ T cells, plasmablast/plasma cells (surface markers as CD19+CD24-CD38hi, CD19+CD27hiCD38hi, CD19+IgD-CD38hi), and CD19+IgD-CD38-CD27+ memory B cells all decreased significantly. The percentage of CD19+IgD+CD38+/- naïve B cells increased after treatment. there were no significance of CD4+CXCR5+ ICOS+ and CD4+CXCR5+PD-1+ TFH, CD19+ total B cells, CD19+CD24hiCD38hi regulatory B cells, CD138+CD38+ plasma cells, CD4+IFN-r+ Th1, CD4+IL17-A+ classical Th17 cells, CD4+ IL-17A+IFN-r+ Th1-like Th17 cells before and after treatment with Iguratimod. Of 30 patients, 23(76.7%) patients had complete remission of clinical symptoms, 3(10.0%) patients had partial remission, and 4 (13.3%) patients had no response to Iguratimod treatment. According to adverse drug reaction, 3 had oral ulcers, two had stomach discomfort, 1 had mild hair loss, and others were well tolerated and had no significant adverse drug reaction.

Conclusion: Iguratimod is effective for the treatment of mild IgG4-RD, it can improve the clinical symptoms of patients, reduce the serum IgG and IgG4 levels, and can also reduce the peripheral blood CD3+CD8+ T, especially plasmablasts/plasma cells, memory B cells, and up-regulate naïve B cells. Besides, Iguratimod can also reduce the plasma IFN-γ levels. So we recommend that it can be used as a first-line treatment for some patients with mild IgG4-RD.


Disclosure: W. Zhang, None; P. Zhang, None.

To cite this abstract in AMA style:

Zhang W, Zhang P. Therapeutic Efficacy and Safety of Iguratimod in Treating Mild IgG4-Related Diseases [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/therapeutic-efficacy-and-safety-of-iguratimod-in-treating-mild-igg4-related-diseases/. Accessed March 21, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-efficacy-and-safety-of-iguratimod-in-treating-mild-igg4-related-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences